drugset / Trial / NCT07647744
To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, dose-escalating Phase 1 clinical study. It aims to evaluate the safety, tolerability and pharmacokinetic(PK) profiles of the investigational agent, and preliminarily assess its efficacy in subjects with advanced/metastatic renal cell carcinoma, and determine the recommended dose and infusion regimen for Phase 2 trials.
Timeline
- Start
- 2026-06-30
- Primary completion
- 2029-06
- Completion
- 2034-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-Human CD70 T-Cell Injection | Cell therapy | 2e+08 cells | — |
| Subject | Anti-Human CD70 T-Cell Injection | Cell therapy | 5e+08 cells | — |
| Subject | Anti-Human CD70 T-Cell Injection | Cell therapy | 1e+09 cells | — |